Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
…, BD Kirkpatrick, J Pullman, T Tong… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2 …
…, A Said, F Tavares-Da-Silva, J Shi, T Tong… - The Lancet Infectious …, 2022 - thelancet.com
Background We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2
preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-…
preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-…
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
…, KH Mayer, L Corey, KM Neuzil, T Tong… - The Journal of …, 2022 - Am Soc Clin Investig
Background We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1
nCoV-19) from an ongoing phase 3 trial. Methods Adults at increased risk of SARS-CoV-2 …
nCoV-19) from an ongoing phase 3 trial. Methods Adults at increased risk of SARS-CoV-2 …
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
…, JG Kublin, MB Isaacs, M Makhene, T Tong… - npj Vaccines, 2023 - nature.com
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines …
…, C Stevens, TP Thuy, R Toma, T Tong… - …, 2023 - thelancet.com
Background In a parallel-group, international, phase 3 study (ClinicalTrials.gov NCT04762680),
we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein …
we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein …
Rapid development of an integrated network infrastructure to conduct phase 3 COVID-19 vaccine trials
…, AR Falsey, RL Tripp, RL Gorman, T Tong… - JAMA network …, 2023 - jamanetwork.com
Importance The COVID-19 pandemic has caused millions of infections and deaths and
resulted in unprecedented international public health social and economic crises. As SARS-CoV-…
resulted in unprecedented international public health social and economic crises. As SARS-CoV-…
Characterization of orderly spatiotemporal patterns of clock gene activation in mammalian suprachiasmatic nucleus
Because we can observe oscillation within individual cells and in the tissue as a whole, the
suprachiasmatic nucleus (SCN) presents a unique system in the mammalian brain for the …
suprachiasmatic nucleus (SCN) presents a unique system in the mammalian brain for the …
Efficacy of a bivalent (D614+ B. 1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind …
…, F Sawe, L Schuerman, T Tong… - The Lancet …, 2023 - thelancet.com
Background COVID-19 vaccines with alternative strain compositions are needed to provide
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
…, F Sawe, L Schuerman, R Shrestha, T Tong… - …, 2023 - thelancet.com
Background The literature on first generation COVID-19 vaccines show they were less effective
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …
[HTML][HTML] Efficacy of a bivalent (D614+ B. 1.351) SARS-CoV-2 protein vaccine
…, SMV Martínez, F Sawe, L Schuerman, T Tong… - medRxiv, 2023 - ncbi.nlm.nih.gov
… Villagómez Martínez, MD, 18 Fredrick Sawe, MBChB, 19 Lode Schuerman, MD, 9 Tina Tong,
DrPH, 5 John Treanor, MD, 20 T. Anh Wartel, MD, 21 Carlos A. Diazgranados, MD, 1, ‡ Roman …
DrPH, 5 John Treanor, MD, 20 T. Anh Wartel, MD, 21 Carlos A. Diazgranados, MD, 1, ‡ Roman …
